Please login to the form below
Sofinnova Partners
This page shows the latest Sofinnova Partners news and features for those working in and with pharma, biotech and healthcare.
Muna raises $73m to advance neurodegenerative disease-focused small molecule pipeline
We are honoured to co-lead this round with Sofinnova Partners, Droia Ventures and LSP Dementia Fund – a tremendous joint effort to bring Muna to the next level,” said Morten Graugaard
Latest news
-
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
Ashrafian, a partner at SV Health Investors, which co-led the Series A with Sofinnova Partners.
-
Illumina sets up first ex-US accelerator site in Cambridge
Cambridge is of course also where Illumina was carrying out the DNA sequencing for the UK’s 100, 000 Genomes Project, in collaboration with Genomics England and other partners such as ... Illumina is joining forces with several venture firms for the
-
Daily Brief: Charity criticises NHSE and Vertex over Orkambi access, Sema scores again, NodThera launched
The fundraising was co-led by leading healthcare investors Sofinnova Partners and 5AM Ventures, with Epidarex Capital and F-Prime Capital Partners also taking part.
-
Morning brief: Allergan’s migraine results, Biktarvy approved in Europe and more
Its investors are Andera Partners (via Europe’s largest life sciences fund Biodiscovery V) and new backers, China’s Quan, plus existing investors Sofinnova Partners, IP Group, EMBL and Takeda Ventures.
-
News in brief, July 04, 2007
Sofinnova Partners, a French investment firm, led the Series A round, joined by additional backers Norway-based NeoMed Management and Bostonís MVM Life Science Partners. ... The lead investor was Special Situations Fund, while other investors were Fort
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
Illumina sets up first ex-US accelerator site in Cambridge
Daily Brief: Charity criticises NHSE and Vertex over Orkambi access, Sema scores again, NodThera launched
Morning brief: Allergan’s migraine results, Biktarvy approved in Europe and more
More from news
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Dr Martin Rothman joins Sofinnova Partners
Rothman brings 40 years of experience along with an international network in the medical field to Sofinnova Partners. ... Rothman said: “I am thrilled to join Sofinnova Partners’ team as venture partner.
-
Kala Pharma appoints Fovea founder Bernard Gilly to board
Prior to his involvement with Fovea, Dr Gilly was a venture partner with Sofinnova Partners from 2000 to 2005.
Dr Martin Rothman joins Sofinnova Partners
Kala Pharma appoints Fovea founder Bernard Gilly to board
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
